<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03746275</url>
  </required_header>
  <id_info>
    <org_study_id>20280</org_study_id>
    <nct_id>NCT03746275</nct_id>
  </id_info>
  <brief_title>Study to Gain Insights in Treatment Patterns and Outcomes in Patients With Atherosclerosis Prescribed to Xarelto in Combination With Acetylsalicylic Acid</brief_title>
  <acronym>XATOA</acronym>
  <official_title>Xarelto + Acetylsalicylic Acid: Treatment Patterns and Outcomes in Patients With Atherosclerosis. A Non-interventional Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study researchers want to gain more information on treatment patterns of patients
      treated with Xarelto in combination with acetylsalicylic acid (ASA). Both drugs reduce the
      risk of blood clots via different pathways. The study will enroll adult patients suffering
      from coronary artery disease (narrowing or blockage of vessels that supply the heart with
      blood) or peripheral artery disease (narrowing or blockage of vessels that supply the legs or
      head with blood). The study will focus on information on when and why physicians are starting
      to treat patients with Xarelto in addition to ASA, treatment duration, reasons to discontinue
      treatment and previous therapies. The study will also look into treatment outcomes for
      patients being treated with a combination of Xarelto and ASA by their physicians.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study aims to collect real-world data on treatment patterns and decision points for
      treatment in patients with coronary artery disease (CAD) and/ or peripheral artery disease
      (PAD) treated with rivaroxaban 2.5 mg [twice daily] for the prevention of major
      cardiovascular events in adult patients with CAD at high risk of ischemic events and/ or
      documented PAD and to describe outcomes of an antithrombotic regime based on dual pathway
      inhibition (vascular dose of rivaroxaban 2.5 mg [twice daily] plus low-dose ASA [once daily])
      across the broad range of patient risk profiles encountered in routine clinical practice.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 13, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 13, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Descriptive analysis of patient history of CAD</measure>
    <time_frame>At baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Descriptive analysis of patient history of PAD</measure>
    <time_frame>At baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Descriptive analysis of prior antithrombotic treatment</measure>
    <time_frame>At baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Descriptive analysis of concomitant antithrombotic treatment</measure>
    <time_frame>Up to 30.5 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Descriptive analysis of prior secondary prevention therapies</measure>
    <time_frame>At baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Descriptive analysis of concomitant secondary prevention therapies</measure>
    <time_frame>Up to 30.5 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Reason for start of rivaroxaban</measure>
    <time_frame>At baseline</time_frame>
    <description>Reasons include past ischemic events, co-morbidities and medical history.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Decision point for start of rivaroxaban</measure>
    <time_frame>At baseline</time_frame>
    <description>Time point of start of medication in relation to disease progress and/ or occurrence of ischemic events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reason for discontinuation of rivaroxaban</measure>
    <time_frame>Up to 30.5 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Planned duration of treatment with rivaroxaban</measure>
    <time_frame>At baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Actual duration of treatment with rivaroxaban</measure>
    <time_frame>Up to 30.5 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Planned duration of treatment with acetylsalicylic acid</measure>
    <time_frame>At baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Actual duration of treatment with acetylsalicylic acid</measure>
    <time_frame>Up to 30.5 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of major adverse cardiac events</measure>
    <time_frame>Up to 30.5 months</time_frame>
    <description>Composite measure of stroke, myocardial infarction and cardiovascular death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of stroke</measure>
    <time_frame>Up to 30.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of myocardial infarction</measure>
    <time_frame>Up to 30.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of cardiovascular death</measure>
    <time_frame>Up to 30.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of major adverse limb events</measure>
    <time_frame>Up to 30.5 months</time_frame>
    <description>Major adverse limb events comprise acute/severe limb ischemia including major amputation and chronic limb ischemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of acute/severe limb ischemia</measure>
    <time_frame>Up to 30.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of chronic limb ischemia</measure>
    <time_frame>Up to 30.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of major amputation</measure>
    <time_frame>Up to 30.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-thrombotic treatment pattern after major adverse limb event</measure>
    <time_frame>Up to 30.5 months</time_frame>
    <description>Treatment pattern comprises drug name, dose and duration of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of thromboembolic events</measure>
    <time_frame>Up to 30.5 months</time_frame>
    <description>Thromboembolic events include systemic embolism and venous thromboembolism.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of haemorrhagic events</measure>
    <time_frame>Up to 30.5 months</time_frame>
    <description>A haemorrhagic event is any event related to bleeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of death from cardiovascular events</measure>
    <time_frame>Up to 30.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of death from any cause</measure>
    <time_frame>Up to 30.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of cardiac revascularization procedures</measure>
    <time_frame>Up to 30.5 months</time_frame>
    <description>Includes percutaneous coronary intervention and coronary artery bypass grafting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of peripheral revascularization procedures</measure>
    <time_frame>Up to 30.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of carotid revascularization procedures</measure>
    <time_frame>Up to 30.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of hospitalizations</measure>
    <time_frame>Up to 30.5 months</time_frame>
    <description>Hospitalizations due to stroke, cardiovascular reasons, major adverse limb events or bleeding complications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>Up to 30.5 months</time_frame>
    <description>Time in days of hospitalization due to stroke, cardiovascular reasons, major adverse limb events or bleeding complications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total walking distance of PAD patients</measure>
    <time_frame>Up to 30.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain-free walking distance of PAD patients</measure>
    <time_frame>Up to 30.5 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">5833</enrollment>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>CAD/PAD-patients</arm_group_label>
    <description>Adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) from Europe, Asia, Latin America and Canada, who are treated with a combination of rivaroxaban and acetylsalicylic acid to prevent atherothrombotic events.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban (BAY59-7939, Xarelto)</intervention_name>
    <description>2.5 mg twice daily</description>
    <arm_group_label>CAD/PAD-patients</arm_group_label>
    <other_name>Xarelto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic acid</intervention_name>
    <description>75 - 100 mg once daily according to local label</description>
    <arm_group_label>CAD/PAD-patients</arm_group_label>
    <other_name>Aspirin</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults in routine medical practice, multi-national
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults with diagnosis Coronary Artery Disease (CAD) or Peripheral Artery Disease
             (PAD).

          -  Treatment according to local marketing authorization, rivaroxaban 2.5 mg twice daily
             started within 4 weeks prior to enrolment. Only in those countries with a marketing
             authorization of rivaroxaban in the acute coronary syndrome (ACS) indication, also
             patients already on rivaroxaban treatment for ACS, who are subsequently fulfilling
             criteria for CAD, are allowed to be enrolled within 4 weeks of this decision being
             made.

        Exclusion Criteria:

          -  Patients who will be treated with chronic anticoagulation therapy other than
             rivaroxaban 2.5 mg given for CAD/PAD.

          -  Participation in an interventional trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Multiple facilities</name>
      <address>
        <city>Multiple Locations</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiple facilities</name>
      <address>
        <city>Multiple Locations</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiple facilities</name>
      <address>
        <city>Multiple Locations</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiple facilities</name>
      <address>
        <city>Multiple Locations</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiple facilities</name>
      <address>
        <city>Multiple Locations</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiple facilities</name>
      <address>
        <city>Multiple Locations</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiple facilities</name>
      <address>
        <city>Multiple Locations</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiple facilities</name>
      <address>
        <city>Multiple Locations</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiple facilities</name>
      <address>
        <city>Multiple Locations</city>
        <country>Luxembourg</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiple facilities</name>
      <address>
        <city>Multiple Locations</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiple facilities</name>
      <address>
        <city>Multiple Locations</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiple facilities</name>
      <address>
        <city>Multiple Locations</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiple facilities</name>
      <address>
        <city>Multiple Locations</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiple facilities</name>
      <address>
        <city>Multiple Locations</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiple facilities</name>
      <address>
        <city>Multiple Locations</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiple facilities</name>
      <address>
        <city>Multiple Locations</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiple facilities</name>
      <address>
        <city>Multiple Locations</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiple facilities</name>
      <address>
        <city>Multiple Locations</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Korea, Republic of</country>
    <country>Lebanon</country>
    <country>Luxembourg</country>
    <country>Mexico</country>
    <country>Norway</country>
    <country>Russian Federation</country>
    <country>Slovenia</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Thailand</country>
    <country>United Arab Emirates</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Saudi Arabia</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Taiwan</country>
  </removed_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 1, 2018</study_first_submitted>
  <study_first_submitted_qc>November 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2018</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary artery disease (CAD)</keyword>
  <keyword>Peripheral artery disease (PAD)</keyword>
  <keyword>Major adverse limb events (MALE)</keyword>
  <keyword>Major adverse cardiac events (MACE)</keyword>
  <keyword>Atherosclerosis</keyword>
  <keyword>Atherothrombosis</keyword>
  <keyword>Thrombosis</keyword>
  <keyword>Embolism</keyword>
  <keyword>Thromboembolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

